News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Cipla completes transfer of Generics Business Undertaking
BHL will undertake the development and supply of these molecules
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
The product has been in-licensed from Strides and will be commercialized by Amneal
Subscribe To Our Newsletter & Stay Updated
